Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBITDA (2016 - 2025)

Cumberland Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 25.56% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$2.8 million, up 56.59%, while the annual FY2025 figure was -$1.4 million, 78.68% up from the prior year.
  • EBITDA for Q4 2025 was -$1.4 million at Cumberland Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.3 million in Q1 2025 and bottomed at -$4.4 million in Q4 2021.
  • The 5-year median for EBITDA is -$1.5 million (2023), against an average of -$1.4 million.
  • The largest annual shift saw EBITDA plummeted 4591.4% in 2024 before it surged 169.12% in 2025.
  • A 5-year view of EBITDA shows it stood at -$4.4 million in 2021, then surged by 47.68% to -$2.3 million in 2022, then grew by 18.05% to -$1.9 million in 2023, then rose by 1.32% to -$1.8 million in 2024, then increased by 25.56% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EBITDA are -$1.4 million (Q4 2025), -$2.0 million (Q3 2025), and -$747478.0 (Q2 2025).